¿Importa la secuencia de tratamiento en egfr +?: Factores que deberían ser considerados
|
SESION 8: NUEVOS ASPECTOS CLÍNICO TERAPÉUTICOS DEL CÁNCER DEPULMÓN EGFR MUTADO¿Importa la secuencia de tratamiento en egfr +?:Factores que deberían ser considerados |
1 |
|
Número de diapositiva 2 |
2 |
|
EGFR Tyrosine Kinase inhibitors |
3 |
|
Número de diapositiva 4 |
4 |
|
Número de diapositiva 5 |
5 |
|
Número de diapositiva 6 |
6 |
|
Número de diapositiva 7 |
7 |
|
Número de diapositiva 8 |
8 |
|
Número de diapositiva 9 |
9 |
|
OSIMERTINIB VS STANDARD-OF-CARE EGFR-TKI AS FIRST-LINE TREATMENT IN PATIENTS WITH EGFRm ADVANCED NSCLC: FLAURA |
10 |
|
PRIMARY ENDPOINT: PFS BY INVESTIGATOR ASSESSMENT |
11 |
|
PFS* across subgroups |
12 |
|
FLAURA: OVERALL SURVIVAL INTERIM ANALYSIS |
13 |
|
Número de diapositiva 14 |
14 |
|
Número de diapositiva 15 |
15 |
|
Número de diapositiva 16 |
16 |
|
Número de diapositiva 17 |
17 |
|
AURA Study Phase II Extension Component (Osimertinib)EGFR Mutations by Last Prior EGFR-TKI Treatment |
18 |
|
Número de diapositiva 19 |
19 |
|
AURA3 primary endpoint: PFS by investigator assessment |
20 |
|
Número de diapositiva 21 |
21 |
|
LUX Lung 7: Afatinib beyond PD |
22 |
|
We do not use RECIST to treat!!!! |
23 |
|
Thinking with summing PFSs………………….. OS impact? |
24 |
|
Can we take ALK disease as an example? |
25 |
|
Final impact on OS can be better than historical |
26 |
|
Is there a winner here? NOT SURE |
27 |
|
Activity of TKIs in EGFR-Mutant NSCLC BM-Models |
28 |
|
Número de diapositiva 29 |
29 |
|
PFS in patients with and without CNS metastases (FLAURA) |
30 |
|
FLAURA: Similar if not better toxicity profile with osimertinib |
31 |
|
TAKE HOME MESSAGES |
32 |
|
Número de diapositiva 33 |
33 |